Direktnyheter • 17h
H.B. Fuller Agrees £715 Million Advanced Medical Solutions Deal as Investors Voice Concerns H.B. Fuller has agreed to acquire UK-based Advanced Medical Solutions in a recommended cash deal worth about £715 million, valuing AMS at £2.85 per share, with closing targeted by the end of this year or by 2026 at the latest, subject to regulatory and shareholder approvals.
The company expects AMS to add roughly $300 million in annual revenue and sees about $55 million of run-rate synergies by 2031, while expanding H.B. Fuller’s medical adhesives and wound care exposure and increasing its total addressable market by an estimated $15 billion.
H.B. Fuller shares trade around $61.95, with the stock down about 4.1% over the past day, as shareholders such as Ancora Holdings Group publicly criticize the deal and question management’s priorities.
The key issue for investors is whether the larger medical platform and targeted synergies adequately compensate for execution risk and the rising tension between H.B. Fuller’s board and some shareholders. Reported Earnings • Jun 25
Second quarter 2026 earnings released: EPS: US$1.25 (vs US$0.77 in 2Q 2025) Second quarter 2026 results: EPS: US$1.25 (up from US$0.77 in 2Q 2025). Revenue: US$950.3m (up 5.8% from 2Q 2025). Net income: US$67.8m (up 62% from 2Q 2025). Profit margin: 7.1% (up from 4.7% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year. Major Estimate Revision • Jun 18
Consensus EPS estimates increase by 12% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from US$3.56 to US$3.97. Revenue forecast steady at US$3.62b. Net income forecast to grow 24% next year vs 32% growth forecast for Chemicals industry in the US. Consensus price target broadly unchanged at US$71.57. Share price was steady at US$64.86 over the past week. Direktnyheter • Jun 18
H.B. Fuller Stock Gets Price Target Boost as Company Pursues Medical and Aerospace Growth UBS raised its price target for H.B. Fuller to $71 from $63 while keeping a Neutral rating and citing expectations for second-quarter 2026 earnings to exceed its prior view and full-year guidance to be raised.
The company is pursuing a bid of more than £600 million for Advanced Medical Solutions Group, aiming to expand its presence in medical adhesives.
H.B. Fuller is investing in oxygen barrier technology through VerdaFresh for recyclable packaging and plans to open an aerospace manufacturing facility to support growth in specialty applications.
Taken together, these moves show H.B. Fuller leaning into higher-value specialty markets such as medical, packaging and aerospace, which can change the company’s mix over time and affect margins and capital needs.
Investors may want to watch how the acquisition process, new facility build-out and technology investments affect H.B. Fuller’s balance sheet, integration costs and execution risk over the next few years. Tillkännagivande • Jun 12
H.B. Fuller Company to Report Q2, 2026 Results on Jun 24, 2026 H.B. Fuller Company announced that they will report Q2, 2026 results After-Market on Jun 24, 2026 Direktnyheter • May 29
H.B. Fuller Invests in VerdaFresh to Support Recyclable High-Performance Packaging Solutions H.B. Fuller announced an investment in VerdaFresh, an advanced oxygen barrier technology used in packaging applications.
VerdaFresh is designed to support fully recyclable mono-material packaging structures while reducing overall material usage.
The company positions this technology as a way to support packaging with a lower environmental footprint and higher performance barrier coatings.
This move highlights H.B. Fuller's focus on packaging solutions that aim to meet both performance and sustainability demands from consumer goods customers.
Investors may want to watch how quickly VerdaFresh-based products are adopted by packaging converters and brand owners, as commercial traction will be key to assessing the financial impact of this technology. Tillkännagivande • May 26
Ancora Holdings Group Releases Letter to H.B. Fuller Company On May 26, 2026, Ancora Holdings Group, LLC announced that it had released a letter to H.B. Fuller Company which outlines the firm’s strong opposition to an acquisition of Advanced Medical Solutions Group plc (“AMS”) or any other business. Ancora stated that it contends the reckless pursuit of AMS Contradicts Management’s March 26 public commitment to avoid near-term deals in favor of necessary deleveraging and highlights the potential acquisition would increase leverage to above 4.0x net debt / proforma adjusted EBITDA and exacerbate the company’s depressed valuation multiple. Ancora added that it noted management lacks experience successfully integrating transformative acquisitions involving new product categories with regulatory complexities in foreign geographies and urged board to abandon its irresponsible pursuit of AMS and conduct a full review of strategic alternatives, including evaluating sale options following apparent buyer interest. Tillkännagivande • May 23
H.B. Fuller Company (NYSE:FUL) proposed to acquire Advanced Medical Solutions Group plc (AIM:AMS). H.B. Fuller Company (NYSE:FUL) proposed to acquire Advanced Medical Solutions Group plc (AIM:AMS) on April 30, 2026. A cash consideration will be paid by H.B. Fuller Company. As part of consideration, an undisclosed value is paid towards common equity of Advanced Medical Solutions Group plc.
The transaction is subject to consummation of due diligence investigation.
Ken Grahame, Soren Moller-Rasmussen, Terres Maloney, Cara Pazdon of Goldman Sachs & Co. LLC acted as financial advisor for H.B. Fuller Company. David Wyles, Charles Spencer, Christian Bradeen and Serdj Balach of Perella Weinberg Partners UK LLP acted as financial advisor for H.B. Fuller Company. Simon Elliott, Julian Oakley, Israel Akinrinsola and Harrison George of Evercore Partners International LLP acted as financial advisor for Advanced Medical Solutions Group plc. Gary Clarence, Harry Hargreaves and Nick Prowting of Investec Bank plc acted as financial advisor for Advanced Medical Solutions Group plc. Declared Dividend • Apr 20
First quarter dividend of US$0.24 announced Shareholders will receive a dividend of US$0.24. Ex-date: 30th April 2026 Payment date: 14th May 2026 Dividend yield will be 1.5%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 6.1% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 29% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Apr 17
H.B. Fuller Company Approves Regular Quarterly Cash Dividend, Payable on May 14, 2026 H.B. Fuller Company announced that its Board of Directors approved an increase in the Company’s regular quarterly cash dividend from $0.2350 per share of common stock to $0.2450 per share of common stock, payable on May 14, 2026 to shareholders of record at the close of business on April 30, 2026. Recent Insider Transactions • Apr 09
President recently bought US$295k worth of stock On the 7th of April, Celeste Mastin bought around 5k shares on-market at roughly US$57.08 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Celeste's only on-market trade for the last 12 months. Reported Earnings • Mar 26
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: US$0.39 (up from US$0.24 in 1Q 2025). Revenue: US$770.8m (down 2.3% from 1Q 2025). Net income: US$21.0m (up 59% from 1Q 2025). Profit margin: 2.7% (up from 1.7% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 42%. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 5% per year. Tillkännagivande • Mar 12
H.B. Fuller Company to Report Q1, 2026 Results on Mar 25, 2026 H.B. Fuller Company announced that they will report Q1, 2026 results After-Market on Mar 25, 2026 Tillkännagivande • Mar 05
H.B. Fuller Company, Annual General Meeting, Apr 16, 2026 H.B. Fuller Company, Annual General Meeting, Apr 16, 2026. Buy Or Sell Opportunity • Feb 23
Now 20% undervalued Over the last 90 days, the stock has risen 12% to US$65.67. The fair value is estimated to be US$82.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 4.1% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Buy Or Sell Opportunity • Feb 05
Now 21% undervalued Over the last 90 days, the stock has risen 13% to US$65.39. The fair value is estimated to be US$82.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to grow by 4.1% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Director Celine Martin was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Jan 28
President exercised options to buy US$816k worth of stock. On the 24th of January, Celeste Mastin exercised options to buy 14k shares at a strike price of around US$60.07, costing a total of US$826k. This transaction amounted to 96% of their direct individual holding at the time of the trade. Since March 2025, Celeste's direct individual holding has increased from 11.99k shares to 19.62k. Company insiders have collectively bought US$1.6m more than they sold, via options and on-market transactions, in the last 12 months. Declared Dividend • Jan 26
Fourth quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 5th February 2026 Payment date: 19th February 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 6.1% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Jan 22
H.B. Fuller Company Announces Regular Quarterly Cash Dividend, Payable on February 19, 2026 H.B. Fuller Company announced that its Board of Directors declared a regular quarterly cash dividend of $0.2350 per share of common stock, payable on February 19, 2026 to shareholders of record at the close of business on February 5, 2026. Reported Earnings • Jan 15
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: US$2.78 (up from US$2.37 in FY 2024). Revenue: US$3.47b (down 2.7% from FY 2024). Net income: US$152.0m (up 17% from FY 2024). Profit margin: 4.4% (up from 3.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%. Revenue is forecast to grow 2.7% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jan 15
H.B. Fuller Company Provides Earnings Guidance for the First Quarter and Fiscal Year 2026 H.B. Fuller Company provides earnings guidance for the first quarter and fiscal year 2026. For the quarter, the company's Net revenue is expected to be down low single digits.
For the year, the company's Net revenue is expected to be flat to up 2%, with organic revenue expected to be approximately flat versus fiscal 2025. Tillkännagivande • Dec 31
H.B. Fuller Company to Report Q4, 2025 Results on Jan 14, 2026 H.B. Fuller Company announced that they will report Q4, 2025 results After-Market on Jan 14, 2026 Recent Insider Transactions Derivative • Nov 14
Insider notifies of intention to sell stock Nathanial Weaver intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 13th of November. If the sale is conducted around the recent share price of US$58.38, it would amount to US$413k. Since March 2025, Nathanial has owned 6.97k shares directly. Company insiders have collectively bought US$2.5m more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Oct 28
Executive VP & CFO notifies of intention to sell stock John Corkrean intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of October. If the sale is conducted around the recent share price of US$60.31, it would amount to US$858k. Since December 2024, John's direct individual holding has increased from 47.19k shares to 52.20k. Company insiders have collectively bought US$2.6m more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Oct 08
H.B. Fuller Company Announces Appointment of Celine Martin to Its Board of Directors, Effective December 1, 2025 H.B. Fuller Company announced the appointment of Celine Martin to its Board of Directors, effective December 1, 2025. Age:51, Ms. Martin brings more than 30 years of experience in the global MedTech industry, with deep expertise across surgical, cardiology, endovascular, and neurovascular segments. Her appointment reinforces H.B. Fuller’s strategic focus on expanding its presence in high-margin, high-growth markets like medical, and supports the company’s transformation journey toward achieving a greater than 20% EBITDA margin. Celine Martin, a seasoned medical device executive, joins H.B. Fuller’s Board of Directors effective December 1, 2025. Ms. Martin most recently served from 2022 to 2025 as the Company Group Chairman of the Cardiovascular & Specialty Solutions (CSS) Group at Johnson & Johnson, a global leader in the research and development, manufacture, and sale of a broad range of medical technologies. As a member of the Johnson & Johnson Medical Devices Group Operating committee, she led a diverse portfolio of medical device businesses including Electrophysiology, Neurovascular Intervention, Ear Nose and Throat and Breast Aesthetics. Before that, Ms. Martin held several roles of increasing responsibilities including Company Group Chairman, overseeing the surgical instrument portfolio of Ethicon, maker of Dermabond topical adhesives, from 2018 to 2021. Over her 30-year career, both in the U.S. and internationally, she played a vital role in advancing the ambition of Johnson & Johnson MedTech, including developing new categories and advancing standards of care for atrial fibrillation, stroke and minimally invasive surgery. Ms. Martin’s three-decade career at Johnson & Johnson included pivotal roles in advancing standards of care for atrial fibrillation, stroke, and minimally invasive surgery. Her global experience and cross-functional leadership in marketing, product development, and commercial strategy make her a strong addition to H.B. Fuller’s Board. Ms. Martin holds an MBA from Wake Forest University and a graduate degree in marketing from EM Normandie Business School. Declared Dividend • Oct 06
Third quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 16th October 2025 Payment date: 30th October 2025 Dividend yield will be 1.6%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (44% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 56% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Oct 03
H.B. Fuller Company Announces Regular Quarterly Cash Dividend, Payable on October 30, 2025 H.B. Fuller Company announced that its Board of Directors declared a regular quarterly cash dividend of $0.2350 per share of common stock, payable on October 30, 2025 to shareholders of record at the close of business on October 16, 2025. Reported Earnings • Sep 25
Third quarter 2025 earnings: EPS exceeds analyst expectations Third quarter 2025 results: EPS: US$1.23 (up from US$1.01 in 3Q 2024). Revenue: US$892.0m (down 2.8% from 3Q 2024). Net income: US$67.2m (up 21% from 3Q 2024). Profit margin: 7.5% (up from 6.0% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 21%. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Tillkännagivande • Sep 25
H.B. Fuller Company Updates Earnings Guidance for the Fiscal 2025 H.B. Fuller Company updated earnings guidance for the fiscal 2025. For the period, Net revenue for fiscal 2025 is expected to be down 2% to 3%; organic revenue for fiscal 2025 is now expected to be flat to up 1%; the company now expect foreign exchange to adversely impact net revenue by approximately 1.0%. Tillkännagivande • Sep 11
H.B. Fuller Company to Report Q3, 2025 Results on Sep 24, 2025 H.B. Fuller Company announced that they will report Q3, 2025 results After-Market on Sep 24, 2025 Declared Dividend • Jul 21
Second quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 31st July 2025 Payment date: 14th August 2025 Dividend yield will be 1.5%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (48% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 117% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Jul 17
H.B. Fuller Company Declares Quarterly Cash Dividend, Payable on August 14, 2025 H.B. Fuller Company announced that its Board of Directors declared a regular quarterly cash dividend of $0.2350 per share of common stock, payable on August 14, 2025 to shareholders of record at the close of business on July 31, 2025. Price Target Changed • Jun 29
Price target increased by 7.6% to US$64.80 Up from US$60.20, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$61.73. Stock is down 20% over the past year. The company is forecast to post earnings per share of US$3.04 for next year compared to US$2.37 last year. Reported Earnings • Jun 26
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: EPS: US$0.77 (down from US$0.93 in 2Q 2024). Revenue: US$898.1m (down 2.1% from 2Q 2024). Net income: US$41.8m (down 18% from 2Q 2024). Profit margin: 4.7% (down from 5.6% in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Tillkännagivande • Jun 26
H.B. Fuller Company Updates Earnings Guidance for Fiscal 2025 H.B. Fuller Company updated earnings guidance for fiscal 2025. As a result of its strong financial performance, the company is updating its previously communicated financial guidance for fiscal 2025. For the period, the company expects Net revenue for fiscal 2025 is now expected to be down 2% to 3%; organic revenue for fiscal 2025 is still expected to be flat to up 2%; company now expect foreign exchange to adversely impact net revenue by 1.0% to 1.5%. Tillkännagivande • Jun 12
H.B. Fuller Company to Report Q2, 2025 Results on Jun 25, 2025 H.B. Fuller Company announced that they will report Q2, 2025 results After-Market on Jun 25, 2025 Declared Dividend • Apr 19
First quarter dividend increased to US$0.23 Dividend of US$0.23 is 5.6% higher than last year. Ex-date: 29th April 2025 Payment date: 13th May 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (66% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 89% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Apr 16
H.B. Fuller Increases Quarterly Dividend, Payable on May 13, 2025 H.B. Fuller company announced that its Board of Directors approved an increase in the Company’s regular quarterly cash dividend from $0.2225 per share of common stock to $0.2350 per share of common stock, payable on May 13, 2025 to shareholders of record at the close of business on April 29, 2025. Buy Or Sell Opportunity • Apr 09
Now 32% overvalued Over the last 90 days, the stock has fallen 15% to US$53.78. The fair value is estimated to be US$40.67, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. Revenue is forecast to grow by 2.9% in 2 years. Earnings are forecast to grow by 102% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$48.43, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Chemicals industry in the US. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$41.11 per share. Price Target Changed • Mar 31
Price target decreased by 8.2% to US$62.40 Down from US$68.00, the current price target is an average from 5 analysts. New target price is 14% above last closing price of US$54.77. Stock is down 31% over the past year. The company is forecast to post earnings per share of US$3.37 for next year compared to US$2.37 last year. Price Target Changed • Mar 28
Price target decreased by 12% to US$63.40 Down from US$71.83, the current price target is an average from 5 analysts. New target price is 16% above last closing price of US$54.77. Stock is down 31% over the past year. The company is forecast to post earnings per share of US$3.37 for next year compared to US$2.37 last year. Tillkännagivande • Mar 28
H.B. Fuller Launches Industry-Changing Commercial Roofing Adhesive with Canister Propellent Technology H.B. Fuller announced the launch of an innovative new technology that is driving change for commercial roofing installation and enhancing environmental responsibility. The H.B. Fuller Millennium PG-1 EF ECO2 is a high-performance roofing adhesive that eliminates the need for chemical blowing agents by using naturally occurring atmospheric gases. This powerful blend of gases called ECO2 Driven™? technology, operates without the use of high Global Warming Potential (GWP) propellants or Hydrofluoroolefins (HFOs), reducing the environmental impact of dispensing the adhesive without compromising adhesion strength. Designed to meet or exceed current North American environmental standards and align with emerging global regulations for Commercial Roofing, Millennium PG-1EF ECO2 is easy to use, while supporting sustainability goals. Canister-based adhesives can help reduce job site waste as canisters offer significant coverage area per unit and, when properly emptied, can be recycled depending on local regulations. As with the first-generation Millennium PG-1 EF ECO product, the "EF" stands for equipment-free. This two-part low-rise foam adhesive efficiently combines part A with part B dispensed through two canisters and features a unique spray nozzle that quickly and easily transitions between a ribbon or spatter spray. This enables the installation of insulation board and fleece-backed roofing membranes with one product that is easy to use and transport. In addition, compared to the mechanical fastening of roofing membranes, adhesives eliminate thermal bridging, achieve high wind uplift ratings, and minimize risks of leaks and building damage during re-roofing. These benefits support H.B. Fuller's commitment to both innovation and sustainability. With performance and patented ECO2 Driven™? Technology, Millennium PG-1 EF ECO 2 helps customers achieve their operational and sustainability goals while delivering value to roofing contractors and building owners. Reported Earnings • Mar 27
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: US$0.24 (down from US$0.57 in 1Q 2024). Revenue: US$788.7m (down 2.7% from 1Q 2024). Net income: US$13.2m (down 57% from 1Q 2024). Profit margin: 1.7% (down from 3.8% in 1Q 2024). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 40%. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Tillkännagivande • Mar 27
H.B. Fuller Company Reaffirms Earnings Guidance for Fiscal Year 2025 H.B. Fuller Company reaffirmed earnings guidance for fiscal year 2025. For the year company expects, Net revenue growth to be down 2% to 4%, adjusting for the divestiture of the Flooring business, net revenue is expected to be up 1% to 2%; Organic revenue growth is expected to be flat to up 2% versus fiscal 2024. Tillkännagivande • Mar 13
H.B. Fuller Company to Report Q1, 2025 Results on Mar 26, 2025 H.B. Fuller Company announced that they will report Q1, 2025 results After-Market on Mar 26, 2025 Price Target Changed • Mar 05
Price target decreased by 9.1% to US$68.60 Down from US$75.50, the current price target is an average from 5 analysts. New target price is 23% above last closing price of US$55.94. Stock is down 29% over the past year. The company is forecast to post earnings per share of US$3.49 for next year compared to US$2.37 last year. Tillkännagivande • Mar 05
H.B. Fuller Company, Annual General Meeting, Apr 15, 2025 H.B. Fuller Company, Annual General Meeting, Apr 15, 2025. New Risk • Jan 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Recent Insider Transactions Derivative • Jan 29
Insider exercised options to buy US$712k worth of stock. On the 26th of January, Zhiwei Cai exercised 11.50k options to receive shares at no cost, then sold around 192.00 of them at US$62.77 each and kept the remainder. Since March 2024, Zhiwei's direct individual holding has decreased from 35.31k shares to 30.66k. Company insiders have collectively sold US$121k more than they bought, via options and on-market transactions in the last 12 months. Declared Dividend • Jan 27
Fourth quarter dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 6th February 2025 Payment date: 20th February 2025 Dividend yield will be 1.4%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (37% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 6.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 55% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Jan 26
Now 20% overvalued Over the last 90 days, the stock has fallen 17% to US$62.77. The fair value is estimated to be US$52.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 5.4%. Revenue is forecast to grow by 0.8% in 2 years. Earnings are forecast to grow by 75% in the next 2 years. Tillkännagivande • Jan 23
H.B. Fuller Company Declares Regular Quarterly Cash Dividend, Payable on February 20, 2025 H.B. Fuller Company announced that its Board of Directors declared a regular quarterly cash dividend of $0.2225 per share of common stock, payable on February 20, 2025 to shareholders of record at the close of business on February 6, 2025. Reported Earnings • Jan 16
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: US$2.37 (down from US$2.67 in FY 2023). Revenue: US$3.57b (up 1.6% from FY 2023). Net income: US$130.3m (down 10% from FY 2023). Profit margin: 3.6% (down from 4.1% in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year. Tillkännagivande • Jan 16
H.B. Fuller Company Provides Consolidated Earnings Guidance for the Fiscal Year 2025 H.B. Fuller Company provided consolidated earnings guidance for the fiscal year 2025. Net revenue growth for fiscal 2025 is expected to be down 2% to 4%, adjusting for the divestiture of the Flooring business, net revenue is expected to be up 1% to 2%; Organic revenue growth is expected to be flat to up 2% versus fiscal 2024. Buy Or Sell Opportunity • Jan 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to US$61.29. The fair value is estimated to be US$77.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Price Target Changed • Jan 03
Price target decreased by 8.6% to US$78.33 Down from US$85.67, the current price target is an average from 6 analysts. New target price is 25% above last closing price of US$62.79. Stock is down 19% over the past year. The company is forecast to post earnings per share of US$3.63 for next year compared to US$2.67 last year. 